Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Tiotropium/Olodaterol Improved Lung Function in Steroid-Free Patients With COPD

Key clinical point: In patients with moderate to severe chronic obstructive pulmonary disease (COPD), treatment with tiotropium/olodaterol combination therapy improves outcomes, compared with tiotropium alone.

Major finding: Patients not receiving inhaled corticosteroids who received tiotropium/olodaterol had a significantly greater improvement in trough forced expiratory volume in 1 second response by week 12 of treatment, compared with patients receiving tiotropium alone (0.054 L; P less than .0001).

Study details: Post hoc analysis of pooled data from the TONADO 1 and 2 and OTEMTO 1 and 2 trials included a total of 1,596 patients with COPD.

Disclosures: Dr. Calverley reported grants and personal fees from GlaxoSmithKline; personal fees from AstraZeneca, Recipharm, and Zambon; and personal and other fees from Boehringer Ingelheim outside the submitted work.

Citation:

Calverley PM et al. CHEST 2019. Abstract, doi: 10.1016/j.chest.2019.08.310.